Eisai (4523) Stock Overview
Engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
4523 Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Eisai Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥4,253.00 |
| 52 Week High | JP¥5,349.00 |
| 52 Week Low | JP¥3,660.00 |
| Beta | -0.072 |
| 1 Month Change | 13.14% |
| 3 Month Change | -15.40% |
| 1 Year Change | 2.98% |
| 3 Year Change | -54.67% |
| 5 Year Change | -60.23% |
| Change since IPO | 161.15% |
Recent News & Updates
Narrative Update • Jul 01
4523: Subcutaneous Alzheimer’s Data And Dosing Expansion Will Support Future Earnings Quality
Analysts have trimmed their fair value estimate for Eisai to ¥5,500 from ¥6,200, citing updated assumptions for profit margins and a higher discount rate, along with a shift to a richer future P/E expectation. What’s in the News for Eisai Eisai plans to present extensive new data on its Alzheimer’s treatment lecanemab (Leqembi) at the Alzheimer’s Association International Conference 2026 in London.Analysis Article • Jun 18
Eisai (TSE:4523) Stock Could Be 21.8% Undervalued After UK Investment Backing
Eisai (TSE:4523) has drawn fresh attention after securing support from the UK Government’s Life Sciences Innovation and Manufacturing Fund for new investment in its UK research, development, and manufacturing operations. See our latest analysis for Eisai. Despite support for Eisai’s UK investment plans, recent share price performance has been weak. The stock is down 17.11% year to date on a share price basis, and the 5 year total shareholder return is also negative. This suggests sentiment...Recent updates
Narrative Update • Jul 01
4523: Subcutaneous Alzheimer’s Data And Dosing Expansion Will Support Future Earnings Quality
Analysts have trimmed their fair value estimate for Eisai to ¥5,500 from ¥6,200, citing updated assumptions for profit margins and a higher discount rate, along with a shift to a richer future P/E expectation. What’s in the News for Eisai Eisai plans to present extensive new data on its Alzheimer’s treatment lecanemab (Leqembi) at the Alzheimer’s Association International Conference 2026 in London.Analysis Article • Jun 18
Eisai (TSE:4523) Stock Could Be 21.8% Undervalued After UK Investment Backing
Eisai (TSE:4523) has drawn fresh attention after securing support from the UK Government’s Life Sciences Innovation and Manufacturing Fund for new investment in its UK research, development, and manufacturing operations. See our latest analysis for Eisai. Despite support for Eisai’s UK investment plans, recent share price performance has been weak. The stock is down 17.11% year to date on a share price basis, and the 5 year total shareholder return is also negative. This suggests sentiment...
Narrative Update • Jun 17
4523: Future Alzheimer And Oncology Progress Will Likely Fail To Justify Premium Price
Analysts have adjusted their fair value estimate for Eisai to ¥3,200 from ¥3,500, reflecting updated assumptions on revenue growth, profit margins, and future P/E following recent sector research. What’s in the News for Eisai Eisai announces a research, development, and manufacturing investment in the UK, supported by the UK Government’s Life Sciences Innovation and Manufacturing Fund, focused on oncology and neurology (source, company announcement).Narrative Update • Jun 03
4523: Future Alzheimer Regulatory Progress Will Likely Just Support Current Valuation
Narrative update on Eisai Analysts have trimmed Eisai's price target from ¥3,674.94 to ¥3,500.00, pointing to updated assumptions around revenue growth, profit margins, discount rate and a higher future P/E multiple, while also factoring in recent sector readthroughs from broader pharmaceutical research coverage. What’s in the News Eisai and BioArctic highlight Leqembi, with reported sales of JPY 143.5b targeted for fiscal 2026 and a simulation presented for around JPY 300b in fiscal 2028, alongside a EUR 20m milestone payment to BioArctic after sales passed EUR 500m in fiscal 2025 (source: Eisai/BioArctic news).
Narrative Update • May 19
4523: Alzheimer’s And Oncology Pipeline Will Support Steady Future Returns
Analysts have nudged their price target on Eisai higher to about ¥5,077 from roughly ¥5,009, citing updated assumptions that include a slightly higher discount rate, modestly adjusted revenue growth and profit margin expectations, and a marginally higher future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts view the higher price target as consistent with Eisai executing broadly in line with updated revenue and margin assumptions, which supports the revised P/E multiple being applied.Narrative Update • May 02
4523: Subcutaneous Alzheimer’s Regimens Will Support Higher Earnings Quality And Future Share Returns
Analysts have maintained their Eisai price target at ¥6,200, citing slightly higher revenue growth assumptions, a modestly lower profit margin outlook, and an updated future P/E of about 19x as the main reasons for keeping their view unchanged. Analyst Commentary Analysts keeping the Eisai price target at ¥6,200 are signaling that current assumptions on revenue growth, margins, and a future P/E of about 19x already capture what they see as the key drivers for the stock.Narrative Update • Apr 17
4523: Future Alzheimer Dosing Approvals Will Still Not Justify Current Price
Analysts have adjusted their price target on Eisai to ¥3,674.94 from ¥3,600, reflecting updated assumptions around more measured revenue growth, a slightly lower profit margin, and a higher future P/E multiple. What's in the News Eisai and MSD submitted a Japanese application for Lenvima in combination with Welireg for unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy, supported by Phase 3 data showing a 30% reduction in risk of disease progression or death versus cabozantinib and no new safety signals (Key Developments).Narrative Update • Apr 03
4523: Alzheimer’s Franchise And Oncology Pipeline Will Support Steady Long Term Outlook
Analysts have trimmed their Eisai price target slightly to ¥5,009 from ¥5,012, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple. What's in the News Eisai and MSD submitted a Japan application for Lenvima in combination with Welireg for unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy, supported by Phase 3 LITESPARK-011 data showing a 30% reduction in risk of disease progression or death versus cabozantinib and a safety profile consistent with each monotherapy (Product-Related Announcements).Narrative Update • Mar 20
4523: Future Alzheimer Dosing Filings Will Still Not Support Current Valuation
Analysts have kept their ¥3,600 price target on Eisai steady, pointing to slightly higher modeled revenue growth, a modestly stronger profit margin outlook, and a lower assumed future P/E as the key drivers behind the updated view. What's in the News The U.S. FDA has granted Priority Review to Eisai's supplemental Biologics License Application for Leqembi Iqlik subcutaneous autoinjector as a weekly starting dose for early Alzheimer's disease, with a PDUFA action date set for May 24, 2026 (Key Developments).Narrative Update • Mar 05
4523: Future Alzheimer Dosing Submissions Will Not Justify Current Share Price
Analysts have kept Eisai's fair value estimate steady at ¥3,600 per share. They cite updated assumptions for slightly higher revenue growth and profit margins, alongside a more conservative future P/E.Narrative Update • Feb 19
4523: Subcutaneous Alzheimer’s Regimens Will Support Higher Margins And Future Share Returns
Analysts have kept their Eisai price target steady at ¥6,200. The latest update reflects slightly softer revenue growth expectations at 7.31%, a modestly higher profit margin outlook of 11.14%, and a small adjustment in assumed future P/E to 18.03x.Analysis Article • Feb 17
Eisai's (TSE:4523) Shareholders Have More To Worry About Than Only Soft Earnings
Eisai Co., Ltd.'s ( TSE:4523 ) stock showed strength, with investors undeterred by its weak earnings report. We think...Analysis Article • Feb 11
Eisai Co., Ltd. (TSE:4523) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Investors in Eisai Co., Ltd. ( TSE:4523 ) had a good week, as its shares rose 8.9% to close at JP¥4,836 following the...Analysis Article • Feb 09
Eisai (TSE:4523) Has Announced A Dividend Of ¥80.00
Eisai Co., Ltd. ( TSE:4523 ) will pay a dividend of ¥80.00 on the 1st of June. This means the annual payment is 3.6% of...Narrative Update • Feb 05
4523: Future Margin Upside From Subcutaneous Alzheimer’s Treatment Will Support Higher Returns
Analysts have lifted their fair value estimate for Eisai to ¥6,200 from ¥6,000, citing updated assumptions that combine a slightly higher discount rate and lower revenue growth with a stronger projected profit margin and a lower future P/E multiple. What's in the News Eisai and BioArctic submitted a Marketing Authorisation Variation to the European Medicines Agency for once every four weeks IV maintenance dosing of lecanemab, following an initial once every two weeks regimen for 18 months in early Alzheimer’s disease.Analysis Article • Jan 26
Eisai's (TSE:4523) Dividend Will Be ¥80.00
Eisai Co., Ltd. ( TSE:4523 ) will pay a dividend of ¥80.00 on the 1st of June. The dividend yield will be 3.5% based on...Narrative Update • Jan 22
4523: Long-Term Alzheimer Injection Shift Will Not Sustain Current Share Price
Analysts have kept Eisai's fair value estimate steady at ¥3,600.0, highlighting modest adjustments to revenue growth, profit margins and future P/E assumptions as they fine tune their price targets rather than rethink the core thesis. What's in the News Regulators in China accepted Eisai's Biologics License Application for a subcutaneous Leqembi autoinjector for early Alzheimer's treatment, with similar filings submitted to the U.S. FDA and Japan's PMDA, targeting at home weekly dosing as an alternative to current IV regimens (Key Developments).Narrative Update • Jan 08
4523: Future Alzheimer Subcutaneous Rollout Will Not Support Current Share Price
Analysts have maintained their price target for Eisai at ¥3,600, citing updated assumptions for revenue growth, profit margins, and future P/E that continue to support the existing valuation framework. What's in the News Regulators in China accepted Eisai's Biologics License Application for a subcutaneous autoinjector formulation of Leqembi for early Alzheimer’s disease, with similar initiation dosing applications also submitted in the U.S. and Japan (Product related announcements) Eisai and partners reported clinical and modeling data at the CTAD conference suggesting long term lecanemab treatment was associated with delayed progression from mild cognitive impairment to more advanced Alzheimer’s stages, with subcutaneous dosing showing drug exposure comparable to intravenous administration (Product related announcements) Multiple filings were completed with the U.S. FDA for Leqembi Iqlik subcutaneous initiation dosing, following earlier approval for subcutaneous maintenance dosing.Analysis Article • Jan 06
Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00
The board of Eisai Co., Ltd. ( TSE:4523 ) has announced that it will pay a dividend of ¥80.00 per share on the 1st of...Narrative Update • Dec 19
4523: Future Alzheimer Data Will Not Justify Current Share Price
Analysts have raised their price target on Eisai to 3,600.00, reflecting improved expectations for revenue growth and slightly stronger profit margins, despite a modest uptick in the assumed discount rate and a marginally lower future P/E multiple. What's in the News New long term data for Alzheimer therapy Leqembi suggest early and continued lecanemab treatment could delay progression from mild cognitive impairment to moderate Alzheimer disease by up to 8.3 years, which supports sustained use and earlier initiation (CTAD conference presentations).Narrative Update • Dec 05
4523: Future Alzheimer’s Pipeline And At Home Treatments Will Support Steady Outlook
Analysts have slightly reduced their price target on Eisai, trimming fair value by about $15 per share to approximately $5,012. They cited marginally lower long term growth and profitability assumptions, while maintaining a similar forward earnings multiple.Analysis Article • Dec 03
Eisai (TSE:4523) Will Pay A Dividend Of ¥80.00
The board of Eisai Co., Ltd. ( TSE:4523 ) has announced that it will pay a dividend on the 1st of June, with investors...Narrative Update • Nov 21
4523: Upcoming Clinical Data And Regulatory Milestones Will Support Steady Long-Term Outlook
Analysts have maintained their price target for Eisai at ¥5,026.92, citing only minor adjustments to revenue growth and profit margin estimates. These adjustments did not significantly influence their overall valuation.Analysis Article • Nov 19
Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00
Eisai Co., Ltd. ( TSE:4523 ) has announced that it will pay a dividend of ¥80.00 per share on the 1st of June. Based on...Analysis Article • Nov 09
Eisai Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Eisai Co., Ltd. ( TSE:4523 ) shareholders are probably feeling a little disappointed, since its shares fell 4.0% to...Narrative Update • Nov 07
4523: Upcoming Regulatory Approvals And Product Launches Will Drive Shares Higher
Narrative Update on Eisai: Analyst Price Target Revision Analysts have maintained their price target for Eisai at ¥5,026.92, citing slightly stronger revised revenue growth forecasts and a modest increase in the discount rate as underlying factors in their valuation assessment. What's in the News Health Canada issued a Notice of Compliance with conditions for LEQEMBI® (lecanemab), making it the first treatment for early Alzheimer's disease that targets an underlying cause to be authorized in Canada.Narrative Update • Oct 24
Global Alzheimer's Advances And Approvals Will Support Long-Term Expansion Prospects
Narrative Update on Eisai Analysts have raised Eisai’s price target modestly from ¥4,988 to ¥5,027. This change reflects slight improvements in revenue growth and profit margin assumptions.Narrative Update • Oct 10
Alzheimer's Biomarker Adoption And Global Rollout Will Fuel Future Opportunity
Analysts have increased their price target for Eisai from ¥4,857.69 to ¥4,988.46. They cite slightly improved profit margin forecasts despite marginally lower expectations for revenue growth.Analysis Article • Sep 22
Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00
Eisai Co., Ltd. ( TSE:4523 ) will pay a dividend of ¥80.00 on the 19th of November. This means the annual payment is...Narrative Update • Sep 11
Alzheimer's Biomarker Adoption And Global Rollout Will Fuel Future Opportunity
The upward revision in the analyst price target for Eisai reflects a modest improvement in consensus revenue growth forecasts, now at 3.9% per annum, supporting the new fair value of ¥4858. What's in the News Eisai expanded its Canadian headquarters in Mississauga, increasing staff by 246% since 2020, demonstrating a firm commitment to R&D and healthcare innovation in Canada.Analysis Article • Sep 08
Eisai (TSE:4523) Has Announced A Dividend Of ¥80.00
Eisai Co., Ltd.'s ( TSE:4523 ) investors are due to receive a payment of ¥80.00 per share on 19th of November. The...Narrative Update • Aug 27
Alzheimer's Biomarker Adoption And Global Rollout Will Fuel Future Opportunity
Eisai's consensus price target saw a marginal increase to ¥4,592, reflecting a slight improvement in revenue growth forecasts, while profit margins remained stable. What's in the News Eisai and Biogen launched LEQEMBI (lecanemab) in Austria and plan to launch in Germany, following EC approval as the first Alzheimer's disease therapy targeting both amyloid plaque and protofibrils, reducing clinical decline by 31% at 18 months versus placebo in the EU indicated population.Analysis Article • Aug 25
Eisai's (TSE:4523) Dividend Will Be ¥80.00
Eisai Co., Ltd. ( TSE:4523 ) has announced that it will pay a dividend of ¥80.00 per share on the 19th of November...Analysis Article • Aug 08
Eisai Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Eisai Co., Ltd. ( TSE:4523 ) just released its quarterly report and things are looking bullish. It was overall a...Analysis Article • Jul 23
Eisai (TSE:4523) Will Pay A Dividend Of ¥80.00
Eisai Co., Ltd.'s ( TSE:4523 ) investors are due to receive a payment of ¥80.00 per share on 19th of November. Based on...Analysis Article • Jul 09
Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00
The board of Eisai Co., Ltd. ( TSE:4523 ) has announced that it will pay a dividend of ¥80.00 per share on the 19th of...Shareholder Returns
| 4523 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | 6.6% | 2.1% | -1.0% |
| 1Y | 3.0% | 15.7% | 41.9% |
Return vs Industry: 4523 underperformed the JP Pharmaceuticals industry which returned 15.7% over the past year.
Return vs Market: 4523 underperformed the JP Market which returned 41.9% over the past year.
Price Volatility
| 4523 volatility | |
|---|---|
| 4523 Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in JP Market | 9.2% |
| 10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4523 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4523's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1941 | 10,543 | Haruo Naito | www.eisai.co.jp |
Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound.
Eisai Co., Ltd. Fundamentals Summary
| 4523 fundamental statistics | |
|---|---|
| Market cap | JP¥1.18t |
| Earnings (TTM) | JP¥38.56b |
| Revenue (TTM) | JP¥825.38b |
31.1x
P/E Ratio1.5x
P/S RatioIs 4523 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4523 income statement (TTM) | |
|---|---|
| Revenue | JP¥825.38b |
| Cost of Revenue | JP¥191.22b |
| Gross Profit | JP¥634.16b |
| Other Expenses | JP¥595.60b |
| Earnings | JP¥38.56b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 03, 2026
| Earnings per share (EPS) | 136.62 |
| Gross Margin | 76.83% |
| Net Profit Margin | 4.67% |
| Debt/Equity Ratio | 20.1% |
How did 4523 perform over the long term?
See historical performance and comparisonDividends
3.8%
Current Dividend Yield117%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/03 07:54 |
| End of Day Share Price | 2026/07/03 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eisai Co., Ltd. is covered by 20 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Miki Sogi | Bernstein |
| Koichi Mamegano | BofA Global Research |